^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GB263T

    i
    Other names: GB263T, GB263tri
    Company:
    Walvax
    Drug class:
    EGFR inhibitor, c-MET inhibitor
    Related drugs:
    2years
    Characterization of GB263T, a tri-specific antibody against EGFR/cMET/cMET for NSCLC (AACR 2022)
    Amivantamab, a bispecific antibody to EGFR/c-Met has shown that concurrent inhibition of EGFR and c-Met can overcome resistance of EGFR-TKIs and improve patient outcomes. GB263T is a novel tri-specific antibody that exhibited robust anti-tumor activity. The preclinical data indicate that GB263T has great potential to become an effective therapeutics in the treatment of NSCLC.
    Late-breaking abstract
    |
    EGFR (Epidermal growth factor receptor) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    EGFR mutation • MET amplification • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • EGFR exon 20 mutation
    |
    Rybrevant (amivantamab-vmjw) • GB263T